6-Keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2

Ernst W Spannhake, James L. Levin, Albert L. Hyman, Philip J. Kadowitz

Research output: Contribution to journalArticle

Abstract

In anesthetized, vagotomized and mechanically ventilated cats, we investigated the bronchodilatory activity of the PGI2 metabolite, 6-keto-PGE1, relative to PGI2 and PGE2. In a range of doses from 0.3-10.0 μg, i.v. injection of 6-keto-PGE1 produced a dose-related decrease in central airway resistance (RL) in animals bronchoconstricted by 5-HT. This effect on RL was 3-10 times greater than that produced by i.v. PGI2. At the lower doses, 6-keto-PGE1 was also more potent than PGI2 in increasing dynamic lung compliance; their effects upon semi-static compliance were not significantly different. Comparison of the bronchopulmonary effects of the two prostanoids did not show any consistent difference in their temporal patterns. In contrast to PGI2 or PGE2, 6-keto-PGE1 had minimal pulmonary vasomotor activity. Inhibition of the cyclooxygenase pathway with sodium meclofenamate had no effect on the bronchopulmonary actions of 6-keto-PGE1 or on its duration of action. These data indicate that 6-keto-PGE1 is a more potent bronchodilator than PGI2 in the cat. They further suggest that conversion of PGI2 to 6-keto-PGE1, if it occurs to an appreciable extent in the lung in vivo, could enhance bronchodilatory activity.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalProstaglandins
Volume21
Issue number2
DOIs
StatePublished - 1981
Externally publishedYes

Fingerprint

Epoprostenol
Cats
Dinoprostone
Meclofenamic Acid
Lung Compliance
Lung
Airway Resistance
Bronchodilator Agents
Prostaglandin-Endoperoxide Synthases
Metabolites
6-ketoprostaglandin E1
Compliance
Prostaglandins
Serotonin
Animals
Injections

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

6-Keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2. / Spannhake, Ernst W; Levin, James L.; Hyman, Albert L.; Kadowitz, Philip J.

In: Prostaglandins, Vol. 21, No. 2, 1981, p. 267-275.

Research output: Contribution to journalArticle

Spannhake, Ernst W ; Levin, James L. ; Hyman, Albert L. ; Kadowitz, Philip J. / 6-Keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2. In: Prostaglandins. 1981 ; Vol. 21, No. 2. pp. 267-275.
@article{71827f1c86bd409ea7e4eb1b23cfc52f,
title = "6-Keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2",
abstract = "In anesthetized, vagotomized and mechanically ventilated cats, we investigated the bronchodilatory activity of the PGI2 metabolite, 6-keto-PGE1, relative to PGI2 and PGE2. In a range of doses from 0.3-10.0 μg, i.v. injection of 6-keto-PGE1 produced a dose-related decrease in central airway resistance (RL) in animals bronchoconstricted by 5-HT. This effect on RL was 3-10 times greater than that produced by i.v. PGI2. At the lower doses, 6-keto-PGE1 was also more potent than PGI2 in increasing dynamic lung compliance; their effects upon semi-static compliance were not significantly different. Comparison of the bronchopulmonary effects of the two prostanoids did not show any consistent difference in their temporal patterns. In contrast to PGI2 or PGE2, 6-keto-PGE1 had minimal pulmonary vasomotor activity. Inhibition of the cyclooxygenase pathway with sodium meclofenamate had no effect on the bronchopulmonary actions of 6-keto-PGE1 or on its duration of action. These data indicate that 6-keto-PGE1 is a more potent bronchodilator than PGI2 in the cat. They further suggest that conversion of PGI2 to 6-keto-PGE1, if it occurs to an appreciable extent in the lung in vivo, could enhance bronchodilatory activity.",
author = "Spannhake, {Ernst W} and Levin, {James L.} and Hyman, {Albert L.} and Kadowitz, {Philip J.}",
year = "1981",
doi = "10.1016/0090-6980(81)90144-1",
language = "English (US)",
volume = "21",
pages = "267--275",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - 6-Keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2

AU - Spannhake, Ernst W

AU - Levin, James L.

AU - Hyman, Albert L.

AU - Kadowitz, Philip J.

PY - 1981

Y1 - 1981

N2 - In anesthetized, vagotomized and mechanically ventilated cats, we investigated the bronchodilatory activity of the PGI2 metabolite, 6-keto-PGE1, relative to PGI2 and PGE2. In a range of doses from 0.3-10.0 μg, i.v. injection of 6-keto-PGE1 produced a dose-related decrease in central airway resistance (RL) in animals bronchoconstricted by 5-HT. This effect on RL was 3-10 times greater than that produced by i.v. PGI2. At the lower doses, 6-keto-PGE1 was also more potent than PGI2 in increasing dynamic lung compliance; their effects upon semi-static compliance were not significantly different. Comparison of the bronchopulmonary effects of the two prostanoids did not show any consistent difference in their temporal patterns. In contrast to PGI2 or PGE2, 6-keto-PGE1 had minimal pulmonary vasomotor activity. Inhibition of the cyclooxygenase pathway with sodium meclofenamate had no effect on the bronchopulmonary actions of 6-keto-PGE1 or on its duration of action. These data indicate that 6-keto-PGE1 is a more potent bronchodilator than PGI2 in the cat. They further suggest that conversion of PGI2 to 6-keto-PGE1, if it occurs to an appreciable extent in the lung in vivo, could enhance bronchodilatory activity.

AB - In anesthetized, vagotomized and mechanically ventilated cats, we investigated the bronchodilatory activity of the PGI2 metabolite, 6-keto-PGE1, relative to PGI2 and PGE2. In a range of doses from 0.3-10.0 μg, i.v. injection of 6-keto-PGE1 produced a dose-related decrease in central airway resistance (RL) in animals bronchoconstricted by 5-HT. This effect on RL was 3-10 times greater than that produced by i.v. PGI2. At the lower doses, 6-keto-PGE1 was also more potent than PGI2 in increasing dynamic lung compliance; their effects upon semi-static compliance were not significantly different. Comparison of the bronchopulmonary effects of the two prostanoids did not show any consistent difference in their temporal patterns. In contrast to PGI2 or PGE2, 6-keto-PGE1 had minimal pulmonary vasomotor activity. Inhibition of the cyclooxygenase pathway with sodium meclofenamate had no effect on the bronchopulmonary actions of 6-keto-PGE1 or on its duration of action. These data indicate that 6-keto-PGE1 is a more potent bronchodilator than PGI2 in the cat. They further suggest that conversion of PGI2 to 6-keto-PGE1, if it occurs to an appreciable extent in the lung in vivo, could enhance bronchodilatory activity.

UR - http://www.scopus.com/inward/record.url?scp=0019394101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019394101&partnerID=8YFLogxK

U2 - 10.1016/0090-6980(81)90144-1

DO - 10.1016/0090-6980(81)90144-1

M3 - Article

C2 - 7012934

AN - SCOPUS:0019394101

VL - 21

SP - 267

EP - 275

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 2

ER -